These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22684865)

  • 1. Causes of death of mutation carriers in Finnish Lynch syndrome families.
    Pylvänäinen K; Lehtinen T; Kellokumpu I; Järvinen H; Mecklin JP
    Fam Cancer; 2012 Sep; 11(3):467-71. PubMed ID: 22684865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
    Järvinen HJ; Renkonen-Sinisalo L; Aktán-Collán K; Peltomäki P; Aaltonen LA; Mecklin JP
    J Clin Oncol; 2009 Oct; 27(28):4793-7. PubMed ID: 19720893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of Lynch syndrome cancers for MSH6 mutation carriers.
    Baglietto L; Lindor NM; Dowty JG; White DM; Wagner A; Gomez Garcia EB; Vriends AH; ; Cartwright NR; Barnetson RA; Farrington SM; Tenesa A; Hampel H; Buchanan D; Arnold S; Young J; Walsh MD; Jass J; Macrae F; Antill Y; Winship IM; Giles GG; Goldblatt J; Parry S; Suthers G; Leggett B; Butz M; Aronson M; Poynter JN; Baron JA; Le Marchand L; Haile R; Gallinger S; Hopper JL; Potter J; de la Chapelle A; Vasen HF; Dunlop MG; Thibodeau SN; Jenkins MA
    J Natl Cancer Inst; 2010 Feb; 102(3):193-201. PubMed ID: 20028993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
    Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
    Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of Lynch syndrome to early onset malignancy in Ireland.
    Talbot A; O'Donovan E; Berkley E; Nolan C; Clarke R; Gallagher D
    BMC Cancer; 2021 May; 21(1):617. PubMed ID: 34039291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
    Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
    Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.
    Pande M; Wei C; Chen J; Amos CI; Lynch PM; Lu KH; Lucio LA; Boyd-Rogers SG; Bannon SA; Mork ME; Frazier ML
    Fam Cancer; 2012 Sep; 11(3):441-7. PubMed ID: 22714864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.
    Obermair A; Youlden DR; Young JP; Lindor NM; Baron JA; Newcomb P; Parry S; Hopper JL; Haile R; Jenkins MA
    Int J Cancer; 2010 Dec; 127(11):2678-84. PubMed ID: 20533284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.
    Mukherjee B; Rennert G; Ahn J; Dishon S; Lejbkowicz F; Rennert HS; Shiovitz S; Moreno V; Gruber SB
    Gastroenterology; 2011 Jun; 140(7):1919-26. PubMed ID: 21419771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.
    Senter L; Clendenning M; Sotamaa K; Hampel H; Green J; Potter JD; Lindblom A; Lagerstedt K; Thibodeau SN; Lindor NM; Young J; Winship I; Dowty JG; White DM; Hopper JL; Baglietto L; Jenkins MA; de la Chapelle A
    Gastroenterology; 2008 Aug; 135(2):419-28. PubMed ID: 18602922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk.
    ten Broeke SW; Brohet RM; Tops CM; van der Klift HM; Velthuizen ME; Bernstein I; Capellá Munar G; Gomez Garcia E; Hoogerbrugge N; Letteboer TG; Menko FH; Lindblom A; Mensenkamp AR; Moller P; van Os TA; Rahner N; Redeker BJ; Sijmons RH; Spruijt L; Suerink M; Vos YJ; Wagner A; Hes FJ; Vasen HF; Nielsen M; Wijnen JT
    J Clin Oncol; 2015 Feb; 33(4):319-25. PubMed ID: 25512458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
    Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
    Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families.
    Choi YH; Lakhal-Chaieb L; Kröl A; Yu B; Buchanan D; Ahnen D; Le Marchand L; Newcomb PA; Win AK; Jenkins M; Lindor NM; Briollais L
    J Natl Cancer Inst; 2019 Jul; 111(7):675-683. PubMed ID: 30380125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer surveillance in Portuguese families with lynch syndrome: a cohort study.
    Vale Rodrigues R; Claro I; Lage P; Rosa I; Ferreira S; Pereira da Silva J; Dias Pereira A
    Int J Colorectal Dis; 2018 Jun; 33(6):695-702. PubMed ID: 29523990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risks for MLH1 and MSH2 mutation carriers.
    Dowty JG; Win AK; Buchanan DD; Lindor NM; Macrae FA; Clendenning M; Antill YC; Thibodeau SN; Casey G; Gallinger S; Marchand LL; Newcomb PA; Haile RW; Young GP; James PA; Giles GG; Gunawardena SR; Leggett BA; Gattas M; Boussioutas A; Ahnen DJ; Baron JA; Parry S; Goldblatt J; Young JP; Hopper JL; Jenkins MA
    Hum Mutat; 2013 Mar; 34(3):490-7. PubMed ID: 23255516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome.
    Mecklin JP; Aarnio M; Läärä E; Kairaluoma MV; Pylvänäinen K; Peltomäki P; Aaltonen LA; Järvinen HJ
    Gastroenterology; 2007 Oct; 133(4):1093-8. PubMed ID: 17919485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-risk by family history and mismatch-repair mutation in Lynch syndrome.
    Marques-de-Sá I; Castro R; Pita I; Dinis-Ribeiro M; Brandão C
    Scand J Gastroenterol; 2020 Jun; 55(6):701-705. PubMed ID: 32448028
    [No Abstract]   [Full Text] [Related]  

  • 18. Decrease in mortality in Lynch syndrome families because of surveillance.
    de Jong AE; Hendriks YM; Kleibeuker JH; de Boer SY; Cats A; Griffioen G; Nagengast FM; Nelis FG; Rookus MA; Vasen HF
    Gastroenterology; 2006 Mar; 130(3):665-71. PubMed ID: 16530507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.
    Renkonen-Sinisalo L; Bützow R; Leminen A; Lehtovirta P; Mecklin JP; Järvinen HJ
    Int J Cancer; 2007 Feb; 120(4):821-4. PubMed ID: 17096354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.
    Stoffel E; Mukherjee B; Raymond VM; Tayob N; Kastrinos F; Sparr J; Wang F; Bandipalliam P; Syngal S; Gruber SB
    Gastroenterology; 2009 Nov; 137(5):1621-7. PubMed ID: 19622357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.